Cytokinetics, Incorporated (NASDAQ:CYTK) Position Lifted by Voya Investment Management LLC

Voya Investment Management LLC increased its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 14.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,463 shares of the biopharmaceutical company's stock after acquiring an additional 10,247 shares during the period. Voya Investment Management LLC owned approximately 0.07% of Cytokinetics worth $3,785,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Cytokinetics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company's stock valued at $560,520,000 after purchasing an additional 154,216 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Cytokinetics by 11.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company's stock valued at $505,780,000 after acquiring an additional 1,062,136 shares in the last quarter. Marshall Wace LLP raised its position in Cytokinetics by 14.9% during the fourth quarter. Marshall Wace LLP now owns 2,153,313 shares of the biopharmaceutical company's stock worth $101,292,000 after acquiring an additional 279,612 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Cytokinetics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company's stock valued at $62,807,000 after purchasing an additional 13,798 shares in the last quarter. Finally, Capital International Investors acquired a new stake in shares of Cytokinetics in the fourth quarter valued at approximately $51,564,000.

Insider Buying and Selling

In related news, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00. Following the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at approximately $5,336,944.58. The trade was a 1.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Andrew Callos sold 3,341 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now directly owns 64,434 shares of the company's stock, valued at $2,788,059.18. This trade represents a 4.93 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 93,360 shares of company stock valued at $3,848,445. Company insiders own 2.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 target price on shares of Cytokinetics in a research note on Monday, April 21st. JMP Securities restated a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a research report on Thursday, April 10th. UBS Group dropped their price objective on Cytokinetics from $47.00 to $41.00 and set a "neutral" rating for the company in a research report on Friday. Bank of America reduced their target price on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating on the stock in a report on Tuesday, April 15th. Finally, Barclays began coverage on shares of Cytokinetics in a report on Thursday, April 24th. They set an "overweight" rating and a $55.00 price target for the company. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $76.88.

Cytokinetics Trading Down 1.8 %

Shares of Cytokinetics stock traded down $0.68 during trading hours on Monday, reaching $36.67. The stock had a trading volume of 2,542,892 shares, compared to its average volume of 1,647,543. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 1 year low of $32.74 and a 1 year high of $68.44. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of -6.82 and a beta of 0.81. The firm has a 50 day simple moving average of $41.35 and a two-hundred day simple moving average of $46.62.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. As a group, equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.